Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark In Talks With Three Firms To Re-license Diabetes Drug

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - India's Glenmark Pharmaceuticals is again in discussions with at least three companies to license out its experimental DPP-4 inhibitor drug melogliptin (GRC 8200), according to a company official

You may also be interested in...



U.S. Court Dismisses Teva’s Patent Infringement Plea Against Dr Reddy’s Carvedilol; Dr Reddy’s May Launch Drug Soon

MUMBAI - Dr Reddy's Labs may be able to sell generic versions of GlaxoSmithKline's hypertension drug Coreg (carvedilol) in the U.S. after it settled a case against Israeli drug maker Teva for four patents of the drug

U.S. Court Dismisses Teva’s Patent Infringement Plea Against Dr Reddy’s Carvedilol; Dr Reddy’s May Launch Drug Soon

MUMBAI - Dr Reddy's Labs may be able to sell generic versions of GlaxoSmithKline's hypertension drug Coreg (carvedilol) in the U.S. after it settled a case against Israeli drug maker Teva for four patents of the drug

Glenmark Continues Search For New Partners As Merck Diabetes Agreement Ends, Reports Strong Q4 Earnings

MUMBAI - Glenmark Phamaceuticals said it is continuing to seek partners to develop its DPP-IV inhibitor melogliptin for type 2 diabetes treatment through outlicensing after it ended an agreement with Merck Serono to develop the drug

Related Content

UsernamePublicRestriction

Register

LL018264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel